FDA clears phentolamine eye drops for presbyopia, creating new U.S. commercial opportunity for Viatris and milestone revenue for Opus Genetics
The FDA approved phentolamine ophthalmic solution 0.75% for presbyopia, expanding the existing RYZUMVI label. The decision opens a large near vision market, triggers a milestone payment to Opus Genetics and hands Viatris exclusive U.S. commercialization rights, reshaping short term revenue prospects for both firms and the competitive ophthalmics landscape.